(Reuters) – Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson’s COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.
Johnson & Johnson had struck a deal with Emergent in April to use its manufacturing facilities and make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
